Investigating the effect of dexmedetomidine on recovery indicators after rhinoplasty surgery

Investigating the preventive effect of dexmedetomidine infusion on recovery indicators after rhinoplasty surgery under general anesthesia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N57

Enrollment

Registered

2022-08-28

Start date

2022-08-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinoplasty. Other and unspecified disorders of nose and nasal sinuses

Interventions

Intervention 1: Control group: half an hour before the end of the surgery, normal saline will be administered in the same volume as the intervention groups in the form of bolus and infusion. Intervent

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age range18 to 65 years Rhinoplasty surgery candidate under general anesthesia American Society of Anesthesiology (ASA) class one and two Consent to participate in the study

Exclusion criteria

Exclusion criteria: Addiction The history of previous allergy to dexmedetomidine body mass index (BMI) above 30 kg/m2 Taking painkillers or neuropsychiatric drugs before the intervention

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: Visual Analogue Scale.;Chilling. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: Based on the shivering criterion (0: no shivering / 1: weak fasciculation of face and neck muscles / 2: visible tremor in more than one muscle group).;Restlessness. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: Riker sedation-agitation scale.	—

Measure

Time frame

Pain. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: Visual Analogue Scale.;Chilling. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: Based on the shivering criterion (0: no shivering / 1: weak fasciculation of face and neck muscles / 2: visible tremor in more than one muscle group).;Restlessness. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: Riker sedation-agitation scale.

—

Secondary

Measure	Time frame
Nausea. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: 0: not having nausea, 1: mild nausea, 2: moderate nausea, and 3: sever nausea.;Vomiting. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: 0: no vomiting, 1: little vomiting, 2: vomiting gastric contents, and 3: vomiting of food particles.	—

Measure

Time frame

Nausea. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: 0: not having nausea, 1: mild nausea, 2: moderate nausea, and 3: sever nausea.;Vomiting. Timepoint: Immediately after entering recovery and then every 15 minutes until leaving recovery. Method of measurement: 0: no vomiting, 1: little vomiting, 2: vomiting gastric contents, and 3: vomiting of food particles.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzim Honarmand

Esfahan University of Medical Sciences

honarmand@med.mui.a.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026